Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Advances in Gene Therapy for Inherited Haemoglobinopathies.

Hematology reports·2026
Same author

Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency.

The New England journal of medicine·2025
Same author

Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant.

Molecular therapy : the journal of the American Society of Gene Therapy·2024
Same author

Targeting the central nervous system in lysosomal storage diseases: Strategies to deliver therapeutics across the blood-brain barrier.

Molecular therapy : the journal of the American Society of Gene Therapy·2022
Same author

Lentiviral Gene Transfer Corrects Immune Abnormalities in XIAP Deficiency.

Journal of clinical immunology·2022

Related Experiment Video

Updated: May 4, 2026

Author Spotlight: Using the Split Retina Technique for Enhanced Access and Accelerated Experiments
07:53

Author Spotlight: Using the Split Retina Technique for Enhanced Access and Accelerated Experiments

Published on: January 16, 2024

4.3K

Tearing RAGs apart.

H Bobby Gaspar1

  • 1UNIVERSITY COLLEGE LONDON INSTITUTE OF CHILD HEALTH.

Blood
|January 11, 2014
PubMed
Summary

Hematopoietic stem cell transplantation (HSCT) for severe combined immunodeficiency (SCID) patients shows myeloablative conditioning improves immune recovery. However, alkylating agents in ARTEMIS deficiency patients increase non-immune complications, highlighting a need for safer strategies.

Area of Science:

  • Immunology
  • Hematology
  • Genetics

Background:

  • Severe combined immunodeficiency (SCID) is a group of rare genetic disorders characterized by profound defects in T-cell and B-cell immunity.
  • Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for SCID, but outcomes can be affected by conditioning regimens and specific genetic mutations.
  • RAG and ARTEMIS mutations represent distinct genetic causes of SCID, potentially influencing treatment response and complication profiles.

Purpose of the Study:

  • To analyze and compare immunologic and nonimmunologic outcomes in SCID patients with RAG or ARTEMIS mutations after HSCT.
  • To identify factors influencing full immunologic recovery and the incidence of nonimmunologic complications.
  • To evaluate the impact of conditioning regimens, specifically myeloablative conditioning and alkylating chemotherapy agents, on HSCT outcomes in different SCID genetic subtypes.

More Related Videos

Two Peeling Methods for the Isolation of Photoreceptor Cell Compartments in the Mouse Retina for Protein Analysis
11:08

Two Peeling Methods for the Isolation of Photoreceptor Cell Compartments in the Mouse Retina for Protein Analysis

Published on: December 7, 2021

3.3K
Preparing Fresh Retinal Slices from Adult Zebrafish for Ex Vivo Imaging Experiments
11:01

Preparing Fresh Retinal Slices from Adult Zebrafish for Ex Vivo Imaging Experiments

Published on: May 9, 2018

8.9K

Related Experiment Videos

Last Updated: May 4, 2026

Author Spotlight: Using the Split Retina Technique for Enhanced Access and Accelerated Experiments
07:53

Author Spotlight: Using the Split Retina Technique for Enhanced Access and Accelerated Experiments

Published on: January 16, 2024

4.3K
Two Peeling Methods for the Isolation of Photoreceptor Cell Compartments in the Mouse Retina for Protein Analysis
11:08

Two Peeling Methods for the Isolation of Photoreceptor Cell Compartments in the Mouse Retina for Protein Analysis

Published on: December 7, 2021

3.3K
Preparing Fresh Retinal Slices from Adult Zebrafish for Ex Vivo Imaging Experiments
11:01

Preparing Fresh Retinal Slices from Adult Zebrafish for Ex Vivo Imaging Experiments

Published on: May 9, 2018

8.9K

Main Methods:

  • Retrospective analysis of patient cohorts with RAG or ARTEMIS mutations undergoing allogeneic HSCT.
  • Comparison of immunologic recovery metrics (e.g., T-cell and B-cell function) between different treatment groups.
  • Assessment of nonimmunologic complications (e.g., organ toxicity, infections) in relation to conditioning agents and genetic mutations.

Main Results:

  • Myeloablative conditioning was associated with a higher likelihood of achieving full immunologic recovery in SCID patients post-HSCT.
  • In patients with ARTEMIS mutations, the use of alkylating chemotherapy agents correlated with an increased incidence of nonimmunologic complications.
  • The study highlights differential impacts of conditioning strategies on immune reconstitution and long-term complications based on SCID genotype.

Conclusions:

  • Achieving complete immunologic recovery while minimizing nonimmunologic complications remains a significant challenge in SCID treatment, particularly for ARTEMIS deficiency.
  • Myeloablative conditioning appears beneficial for immune reconstitution but may carry risks for nonimmunologic outcomes in specific genetic contexts.
  • Future research should explore novel conditioning agents or gene therapy to optimize HSCT outcomes for SCID patients, balancing efficacy and safety.